Acadia Pharma (ACAD) Tops Q3 EPS by 17c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.50 -2.75%
Revenue Growth %: +11.9%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, PXED, AEHR, More
Revenue Growth %: +11.9%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, PXED, AEHR, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $131.6 million versus the consensus estimate of $127.75 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Piper Sandler Upgrades Patterson-UTI Energy (PTEN) to Overweight
- Gold Royalty acquires two Nevada royalties for $0.8 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
